Found: 40
Select item for more details and to access through your institution.
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01167-8
- By:
- Publication type:
- Article
An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications.
- Published in:
- BJU International, 2008, v. 101, n. 6, p. 712, doi. 10.1111/j.1464-410X.2007.07268.x
- By:
- Publication type:
- Article
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Lenalidomide‐based response‐adapted therapy for older adults without high risk myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 5, p. 735, doi. 10.1111/bjh.15700
- By:
- Publication type:
- Article
Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 2, p. 231, doi. 10.1111/bjh.15394
- By:
- Publication type:
- Article
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 2, p. E54, doi. 10.1002/ajh.26420
- By:
- Publication type:
- Article
CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation.
- Published in:
- Bioinformatics, 2022, v. 38, n. 16, p. 4002, doi. 10.1093/bioinformatics/btac417
- By:
- Publication type:
- Article
Lenalidomide in Patients with Multiple Myeloma who have Received One Prior Therapy.
- Published in:
- Asia Pacific Journal of Oncology & Hematology, 2010, v. 2, n. 1, p. 23
- By:
- Publication type:
- Article
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4711, doi. 10.3390/cancers15194711
- By:
- Publication type:
- Article
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2017, v. 8, n. 7, p. 209, doi. 10.1177/2040620717710171
- By:
- Publication type:
- Article
Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 6, p. 507, doi. 10.1016/j.clml.2011.06.010
- By:
- Publication type:
- Article
Prediction of Response and Progression in Multiple Myeloma With Serum Free Light Chains Assay: Corroboration of the Serum Free Light Chain Response Definitions.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 1, p. E10, doi. 10.3816/CLML.2010.n.010
- By:
- Publication type:
- Article
State-of-the-Art Management of Complications of Myeloma and Its Treatment.
- Published in:
- Advances in Hematology, 2010, v. 2010, p. 1, doi. 10.1155/2010/343089
- By:
- Publication type:
- Article
An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
- Published in:
- European Journal of Haematology, 2015, v. 95, n. 5, p. 426, doi. 10.1111/ejh.12509
- By:
- Publication type:
- Article
Impact of Remission Induction Chemotherapy on Survival in Older Adults With Acute Myeloid Leukemia.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 8, p. 1752, doi. 10.1002/cncr.22976
- By:
- Publication type:
- Article
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 11, p. 2609, doi. 10.1002/cncr.22290
- By:
- Publication type:
- Article
Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasiasPresented in poster form at the 44th Annual Meeting of the American Society of Hematology, Philadelphia, December 2002: A retrospective review.
- Published in:
- Cancer (0008543X), 2004, v. 101, n. 4, p. 790
- By:
- Publication type:
- Article
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e770, doi. 10.1016/j.clml.2022.04.003
- By:
- Publication type:
- Article
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. e414, doi. 10.1016/j.clml.2021.12.008
- By:
- Publication type:
- Article
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Twice-weekly Ixazomib plus Lenalidomide-dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-term Follow-up Data for Patients Not Undergoing Stem Cell Transplantation (SCT).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S337, doi. 10.1016/j.clml.2017.07.152
- By:
- Publication type:
- Article
Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 11, p. 1244, doi. 10.1002/ajh.25627
- By:
- Publication type:
- Article
Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 4, p. 349, doi. 10.1002/ajh.23639
- By:
- Publication type:
- Article
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 1, p. 62, doi. 10.1002/ajh.23587
- By:
- Publication type:
- Article
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.
- Published in:
- Cellular Oncology (2211-3428), 2011, v. 34, n. 6, p. 545, doi. 10.1007/s13402-011-0060-6
- By:
- Publication type:
- Article
Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 8, p. 983, doi. 10.1080/0284186X.2020.1772499
- By:
- Publication type:
- Article
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0304-z
- By:
- Publication type:
- Article
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 5, p. 1, doi. 10.1111/cts.13828
- By:
- Publication type:
- Article
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Bortezomib salvage followed by a Phase I/ II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 157, n. 5, p. 553, doi. 10.1111/j.1365-2141.2012.09099.x
- By:
- Publication type:
- Article
Does low-dose aspirin have antineoplastic effects in multiple myeloma?
- Published in:
- 2006
- By:
- Publication type:
- Letter
Multiple myeloma presenting as an intramedullary spinal cord tumor: a case report and review of the literature.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Quality Improvement at an Academic Cancer Center: Venous Thromboembolism Prophylaxis in Patients With Multiple Myeloma.
- Published in:
- Cancer Control: Journal of the Moffitt Cancer Center, 2020, v. 27, n. 2, p. 1, doi. 10.1177/1073274820930204
- By:
- Publication type:
- Article
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.
- Published in:
- Oncology & Therapy, 2016, v. 4, n. 2, p. 287, doi. 10.1007/s40487-016-0034-y
- By:
- Publication type:
- Article
Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients.
- Published in:
- Proteomics - Clinical Applications, 2014, v. 8, n. 10, p. 783, doi. 10.1002/prca.201300077
- By:
- Publication type:
- Article
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Multiple Myeloma Genomics -- A Concise Review.
- Published in:
- Acta Medica Academica, 2019, v. 48, n. 1, p. 57, doi. 10.5644/ama2006-124.242
- By:
- Publication type:
- Article